Treatment using soluble IL-17 receptor fusion protein or anti-IL-17 antibody can enhance the severity of arthritis, cartilage injury, and bone loss (Lubberts et al., 2001; Bush et al., 2002; Lubberts et al., 2004; Pöllinger et al., 2011). The gene discussed is IL17A; the disease is arthritic joint disease.